Lok Chui-Lin. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 142-157). / Abstracts in English and Chinese. / Statement --- p.I / Acknowledgement --- p.II / Abstract --- p.IV / Chinese Abstract (摘要） --- p.VI / Abbreviation --- p.VIII / Table of Contents --- p.XIII / List of Tables --- p.XVII / List of Figures --- p.XVIII / Chapter Chapter One : --- Literature Review --- p.1 / Chapter 1.1 --- The Schistosoma Species --- p.1 / Chapter 1.1.1 --- The Schistosoma Gene Discovery --- p.3 / Chapter 1.1.2 --- Schistosome Transcriptome --- p.4 / Chapter 1.2 --- Schistosomiasis --- p.4 / Chapter 1.2.1 --- Immunopathology of Schistosomiasis --- p.5 / Chapter 1.2.2 --- Diagnosis of Schistosomiasis --- p.7 / Chapter 1.2.3 --- Treatment and Control for Schistosomiasis --- p.7 / Chapter 1.2.4 --- Vaccine Development for Schistosomiasis --- p.8 / Chapter 1.3 --- "The Species, Schistosoma japonicum" --- p.9 / Chapter 1.3.1 --- The Life Cycle of Schistosoma japonicum --- p.10 / Chapter 1.3.1.1 --- "The Egg, Miracidium Phase of the Life Cycle" --- p.12 / Chapter 1.3.1.2 --- Developmental Cycle within Mollusc Host --- p.12 / Chapter 1.3.1.3 --- The Cercaria Phase of Life Cycle --- p.13 / Chapter 1.3.1.4 --- Adult Schistosome in Definitive Host --- p.14 / Chapter 1.4 --- Invasion by Schistosome Cercariae --- p.15 / Chapter 1.5 --- "The Anti-inflammatory Protein, Sml6" --- p.16 / Chapter 1.5.1 --- Discovery of Sm 16 --- p.16 / Chapter 1.5.2 --- Cloning and Expression of Gene-encoding Sm 16 --- p.17 / Chapter 1.5.3 --- Potential Anti-inflammatory Therapy using Sm 16 --- p.18 / Chapter 1.6 --- Innate Immunity and Adaptive Immunity --- p.18 / Chapter 1.6.1 --- Macrophage --- p.18 / Chapter 1.6.2 --- Major Histocompatiblity Complex (MHC) --- p.20 / Chapter 1.6.3 --- Adaptive Immunity to Parasites --- p.20 / Chapter 1.7 --- Inflammation --- p.21 / Chapter 1.7.1 --- Cells of the Inflammatory Process --- p.23 / Chapter 1.7.2 --- Cytokines --- p.24 / Chapter 1.7.2.1 --- Interleukin-1 (IL-1) System --- p.26 / Chapter 1.7.2.2 --- Interferon (IFN) System --- p.27 / Chapter 1.7.3 --- Anti-inflammatory Therapy --- p.28 / Chapter 1.8 --- Aim of Study --- p.29 / Chapter Chapter Two : --- Materials and Methods --- p.30 / Chapter 2.1 --- Materials --- p.30 / Chapter 2.1.1 --- "Cell Lines, Mouse Strain and Bacterial Strains" --- p.30 / Chapter 2.1.2 --- Plasmids --- p.31 / Chapter 2.1.3 --- Chemicals --- p.31 / Chapter 2.1.4 --- "Kits, Nucleic Acids and Reagents" --- p.34 / Chapter 2.1.5 --- Antibodies and Immunoglobins --- p.35 / Chapter 2.1.6 --- Cell Culture Reagents --- p.35 / Chapter 2.1.7 --- Solutions --- p.36 / Chapter 2.1.8 --- Solutions of Reaction Kits --- p.39 / Chapter 2.1.9 --- Enzymes --- p.41 / Chapter 2.1.10 --- Major Equipments and Materials --- p.41 / Chapter 2.1.11 --- Primers --- p.43 / Chapter 2.1.11.1 --- Sequencing and Sj 16 Gene-coding Specific Primers --- p.43 / Chapter 2.1.11.2 --- Primers for Cytokines --- p.43 / Chapter 2.2 --- Methods --- p.45 / Chapter 2.2.1 --- Amplification of Sjl6 cDNA from Schistosoma japonicum Cercariae --- p.45 / Chapter 2.2.1.1 --- Isolation of Cercariae total RNA by Guanidinium Thiocyanate - Cesium Chloride Ultracentrifugation --- p.45 / Chapter 2.2.1.2 --- Reverse Transcription - Polymerase Chain Reaction (RT-PCR) --- p.46 / Chapter 2.2.1.2.1 --- Reverse Transcription (RT) --- p.46 / Chapter 2.2.1.2.2 --- Polymerase Chain Reaction (PCR) --- p.46 / Chapter 2.2.2 --- Cloning and Subcloning of Sj 16 --- p.47 / Chapter 2.2.2.1 --- Preparation of DH5a Competent Cells --- p.47 / Chapter 2.2.2.2 --- Purification of Plasmid DNA --- p.48 / Chapter 2.2.2.3 --- Restriction Enzyme Digestion of DNA --- p.49 / Chapter 2.2.2.4 --- Purification of DNA Fragments from Agarose Gel --- p.50 / Chapter 2.2.2.5 --- Ligation of Purified DNA Fragments --- p.51 / Chapter 2.2.2.6 --- Transformation of Recombinant Plasmid --- p.52 / Chapter 2.2.2.7 --- Selection of Transformed Clones --- p.52 / Chapter 2.2.2.7.1 --- Screening by X-gal and IPTG : a-complementation --- p.52 / Chapter 2.2.2.7.2 --- Screening by Polymerase Chain Reaction --- p.53 / Chapter 2.2.2.8 --- Cycle Sequencing --- p.53 / Chapter 2.2.3 --- Expression of the rSj 16 in Eukaryotic System --- p.55 / Chapter 2.2.3.1 --- Transfection of pSecTag2B/Sj 16 Plasmid into Animal Cells --- p.55 / Chapter 2.2.3.2 --- PCR Screening of Transfected Cells --- p.56 / Chapter 2.2.3.3 --- Analysis of mRNA Transcript by RT-PCR --- p.56 / Chapter 2.2.3.4 --- Concentration of the Condition Medium --- p.57 / Chapter 2.2.3.5 --- Western Blot analysis of rSjl6 Expression --- p.58 / Chapter 2.2.4 --- Expression of rSjl6 in Bacterial System --- p.59 / Chapter 2.2.4.1 --- Transformation of pET30a+/Sjl6 Plasmid into BL21 --- p.59 / Chapter 2.2.4.2 --- Optimization of rSj 16 Expression --- p.60 / Chapter 2.2.4.3 --- Solubility of the rSjl6 --- p.60 / Chapter 2.2.4.4 --- Estimation of rSj 16 Concentration --- p.62 / Chapter 2.2.4.5 --- Western Blot Analysis of rSj 16 --- p.62 / Chapter 2.2.5 --- Recombinant Protein Purification --- p.63 / Chapter 2.2.5.1 --- Affinity Chromatography of Recombinant Protein --- p.63 / Chapter 2.2.5.2 --- Dialysis of Eluted Recombinant Protein in PBS --- p.64 / Chapter 2.2.5.3 --- Estimation of Recombinant Protein Concentration --- p.65 / Chapter 2.2.6 --- Demonstrate the Anti-inflammatory Activity of rSj 16 --- p.65 / Chapter 2.2.6.1 --- Thioglycollate Induced Macrophage Recruitment --- p.65 / Chapter 2.2.6.2 --- Cytospin and Hemacolor Staining of PECs --- p.66 / Chapter 2.2.6.3 --- FACS Analysis of PECs --- p.67 / Chapter 2.2.6.4 --- Isolation of total RNA by TRIZOL Reagent --- p.67 / Chapter 2.2.7 --- Immunogenicity and Antigenicity of rSjl6 --- p.68 / Chapter 2.2.7.1 --- Western Blot of rSjl6 with Schistosoma japonicum infected rabbit serum --- p.69 / Chapter 2.2.7.2 --- Preparation of Anti-Sj 16 Serum --- p.69 / Chapter 2.2.7.3 --- Western Blot of rSjl6 with immunized mice serum --- p.70 / Chapter 2.2.8 --- FACS analysis of MHC (I) Expression --- p.71 / Chapter 2.2.9 --- Anti-proliferative Assay using BrdU Kit --- p.72 / Chapter Chapter Three : --- Results --- p.73 / Chapter 3.1 --- Amplification of Sj 16 cDNA from Schistosoma japonicum Cercariae total RNA --- p.73 / Chapter 3.2 --- Construction of pBluescript II SK(-) / Sjl6 --- p.75 / Chapter 3.3 --- Analysis of Sj 16 Nucleotide and Amino Acid Sequence --- p.78 / Chapter 3.3.1 --- Blastn Search Analysis --- p.80 / Chapter 3.3.2 --- Blastx Search Analysis --- p.82 / Chapter 3.3.3 --- Structural Analysis --- p.84 / Chapter 3.4 --- Subcloning of Sjl6 cDNA into pET30a+ and pSecTag2B Expression Vector --- p.88 / Chapter 3.5 --- Expression of the rSj 16 --- p.92 / Chapter 3.5.1 --- Animal Cell Expression --- p.92 / Chapter 3.5.1.1 --- Analysis of mRNA Transcript by RT-PCR --- p.93 / Chapter 3.5.1.2 --- Western Blot of Condition Medium --- p.95 / Chapter 3.5.2 --- Bacterial Cell Expression --- p.97 / Chapter 3.5.2.1 --- Optimization of rSjl6 Expression --- p.97 / Chapter 3.5.2.2 --- Estimation of rSjl6 Concentration --- p.98 / Chapter 3.5.2.3 --- Solubility of rSj16 --- p.99 / Chapter 3.5.2.4 --- Western Blot Analysis of rSjl6 --- p.100 / Chapter 3.6 --- Purification of Recombinant Protein --- p.101 / Chapter 3.6.1 --- Purification of rSj16 --- p.101 / Chapter 3.6.2 --- Purification of rSjCa8 --- p.104 / Chapter 3.7 --- Anti-inflammatory Activity of rSj 16 --- p.107 / Chapter 3.7.1 --- Analysis of PECs in Thioglycollate Induced Inflammation --- p.107 / Chapter 3.7.2 --- Hemacolor Staining of PECs --- p.110 / Chapter 3.7.3 --- FACS Analysis of PECs --- p.110 / Chapter 3.7.4 --- RT-PCR of RNA Isolated from PECs --- p.115 / Chapter 3.8 --- Immunogenicity and Antigenicity of rSjl6 --- p.117 / Chapter 3.8.1 --- Immunogenicity of rSj 16 --- p.117 / Chapter 3.8.2 --- Antigenicity of rSj16 --- p.117 / Chapter 3.9 --- Inhibitory Effect of rSj 16 on rMuIFN-a4 Induced Up-regulation of MHC(I) Expression --- p.120 / Chapter 3.9.1 --- Time Course of rMuIFN-α4 Induced Up-regulation of MHC(I) Expression --- p.120 / Chapter 3.9.2 --- Inhibitory Effect of rSjl6 on rMuIFN-α4 Induced MHC (I) Up-regulation --- p.120 / Chapter 3.9.3 --- "Anti-proliferation Effect of rMuIFN-a4, rSj 16 and rSjCa 8" --- p.124 / Chapter 3.9.4 --- Effect of Signal Transduction Inhibitors on rMuIFN-a4 Induced MHC (I) Up-regulation --- p.126 / Chapter Chapter Four : --- Discussion and Conclusion --- p.129 / Chapter 4.1 --- Discussion --- p.129 / Chapter 4.1.1 --- Overview --- p.129 / Chapter 4.1.2 --- Molecular and Structural Analysis of rSj 16 --- p.130 / Chapter 4.1.3 --- Relationship between Sml6 and Sjl6 --- p.131 / Chapter 4.1.4 --- Anti-inflammatory Activity of rSj 16 --- p.132 / Chapter 4.1.5 --- Immunogenicity and Antigenicity of rSjl6 --- p.137 / Chapter 4.1.6 --- Inhibitory Effect of rSjl6 on rMuIFN-a4 Induced Up-regulation of MHC (I) Expression --- p.138 / Chapter 4.1.7 --- Relation between Sj 16 and the Innate Immune System --- p.139 / Chapter 4.1.8 --- Further Study and Significance --- p.140 / Chapter 4.2 --- Conclusion --- p.141 / References --- p.142

Thesis (M.S.)--West Virginia University, 2002. / Title from document title page. Document formatted into pages; contains viii, 51 p. : ill. Includes abstract. Includes bibliographical references (p. 39-42).

Thesis (M.S.)--West Virginia University, 2005. / Title from document title page. Document formatted into pages; contains viii, 59 p. : ill. (some col.). Vita. Includes abstract. Includes bibliographical references (p. 33-38).

Thesis (M.S.)--University of Louisville, 1997. / eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (M.S.)--University of Louisville, 1997. / Includes bibliographical references.

Thesis (Ph. D.)--University of Oklahoma. / Bibliography: leaves 168-181.

published_or_final_version / abstract / Medicine / Doctoral / Doctor of Philosophy

Our hypothesis is that the polyamine biosynthetic pathway, a pathway essential in many cellular functions, is modulated by NSAIDs and that this is, at least in part, how NSAID chemoprevention is mediated. An <i>in vitro </i>model of colorectal cancer was used: two cell lines one of which is COX positive and one COX negative to determine the effects of a range of selective and non-selective NSAIDs on various reactions within the polyamine pathway.  NSAIDs are cytotoxic to colorectal cancer cells regardless of their COX expression.  NSAID-mediated inhibition of cell growth is accompanied by inhibition of ODC activity, partial depletion of polyamine concentrations and up-regulation of polyamine catabolism. In order to investigate the importance of polyamine metabolism, a specific polyamine inhibitor α-difluoromethylornithine (DFMO) was used in combination with the NSAIDs.  DFMO <i>per se </i>is not toxic to cells and it does not enhance NSAID mediated toxicity.  DFMO in combination with the NSAIDs did cause increased catabolic activity and more sustained polyamine depletion than either alone, however no additional decrease in ODC activity was observed.  This suggests that NSAID toxicity is not enhanced by DFMO in this <i>in vitro </i>model. Analysis of the mode of death indicated that the NSAIDs caused apoptotic cell death, confirmed through biochemical and morphological studies and that the NSAIDs affected gene expression of key enzymes in the polyamine biosynthetic pathway. Our findings suggest that modulation of the polyamine pathway by NSAIDs is at least part of the mechanism of action involved in cancer chemoprevention. Therefore modulation of the polyamine pathway may be useful for design of new chemopreventative drugs.

Colorectal neoplasia (CRN) continues to be a leading cause of morbidity and mortality in the developed world and with westernisation, similar trends are now emerging in the developing world. Although secondary prevention through screening programmes has reduced mortality, uptake remains poor due to the invasive nature of colonoscopy, which also exerts increased costs to the health care system. Primary prevention remains the ultimate aim to reduce the morbidity and mortality associated with CRN. In this regard, chemoprevention strategies through regular use of aspirin and other NSAIDS have showed great promise but the associated significant side-effects of these drugs has prevented their routine clinical application for this purpose. Hence there is an urgent need for the identification of safer alternatives for primary prevention of CRN. In parallel to this search, better understanding of the molecular pathogenesis of CRN to identify biomarkers that aid in stratification of at risk individuals would also help. In this regard, the role of chronic inflammation and the influence of host genetics in the pathogenesis of CRN has been the focus of extensive research in recent years. However there is a lack of studies which have investigated these associations in an exclusively screened population, which confers some advantages for this type of investigation. Firstly, most of the screened subjects are relatively healthy, asymptomatic and with no significant co-morbidities, the factors which could otherwise influence the levels of inflammatory markers. Secondly, the screened population is in the 50 to74 year age group which represents the group with a high prevalence of CRN and hence increasing the possibility of finding associations which would be more relevant and generalisable. Thirdly, the selected controls match the cases in all important respects, apart from having CRN, thus increasing the validity of the findings in this population. The Grampian region was one of the first in the UK to participate in the National Colorectal Cancer Screening Programme and this resource gave the ideal opportunity to conduct research involving an exclusively screened population. Utilising this cohort, the current thesis addressed three important aspects of the association between inflammation and CRN. Firstly the investigation of the association of inflammatory genotype, inflammatory phenotype and CRN risk. Secondly the impact of environmental factors, specifically dietary antiinflammatory salicylic acid intakes on CRN risk. And finally assessing if inflammation, and hence in the long term risk of CRN, could be attenuated through a comprehensive anti-inflammatory dietary supplementation in the form of a randomised dietary intervention clinical trial. The study of the association of polymorphisms in key inflammatory genes (IL1B- 31, IL8-251, IL6-174, TNFα-308, IL10-1082, IL10-592, PTGS2-765, and IL1RN VNTR) and CRN risk showed some significant findings. A novel finding was that the homozygous IL1B-31C*C genotype was associated with statistically significant increased risk of CRN, OR 1.63 (95% CI 1.06-2.50) whilst the IL8-251 A*A genotype increased the propensity of having high risk lesions by two-fold (OR 2.04; 95% CI 1.02-4.07). The study of circulating inflammatory marker levels in subjects in whom the CRN was in-situ showed that increased CRP levels were associated with increased risk of CRN, OR 1.55 (95% CI 1.00-2.39). Increased levels of IL8 were associated with increased risk of having a high risk lesion, OR 2.57 (95% CI 1.03-6.44). In a sub group of subjects, it was observed that levels IL8 and CRP decreased following polypectomy (mean IL8 20.3 pg/ml to 14.9 pg/ml, p=0.05 and mean CRP 5.99 mg/l to 3.82 mg/l, p=0.07) raising an important question regarding the sequence of the inflammation-neoplasia cascade, “Is inflammation the cause or the effect of neoplasia?” The study of the association of dietary salicylic acid (SA) and CRN using the newly constructed SA database showed that high levels of total SA (aspirin and dietary SA) intakes were associated with a 75% and moderate levels with a 67% decreased risk of CRN. But dietary SA on its own showed no significant effect on CRN risk probably because of low intake levels in the current cohort. Applying the SA database to populations with higher dietary SA intake would help to further explore its association with CRN risk. The randomised clinical trial examining the effect of a combined antiinflammatory dietary supplement (curcumin, omega-3 PUFA and polyphenols rich fruit smoothie) on markers of inflammation in subjects who had adenomatous colorectal polyps removed showed that the inflammatory marker levels in the control group who just continued their habitual diet remained stable without any statistically significant changes at 6 weeks compared to the baseline. Whereas following 6 weeks of dietary intervention, there was marginally significant increase in IL8 and IL1B levels. One of the possible mechanisms for increase in pro-inflammatory marker levels in the intervention group was the weight gain seen in the intervention group. In the intervention group, the post-intervention mean weight (86.80kgs) was significantly higher than the pre-intervention mean weight (85.38 kgs). In summary, the findings from these investigations suggest that a proinflammatory genotype (IL1B-31C*C and IL8-251 A*A) and elevated circulating inflammatory marker levels (CRP and IL8) are associated with increased risk of CRN. And along with the findings that regular NSAID use and total dietary SA are associated with decreased risk of CRN, our data point to inflammation as an underlying pathogenetic mechanism in CRN. The pilot clinical trial has demonstrated that a clinical trial with combined dietary supplementation is feasible, but challenging. The anti-inflammatory dietary intervention strategy employed to reduce the inflammatory markers did not achieve the desired effect and hence more research is required to establish the ideal delivery strategy of the anti-inflammatory dietary agents. Once this is established, dietary chemoprevention of CRN as a safe alternative should be a realistic achievable goal in the future.

Dissertation submitted to the Faculty of Health in partial compliance with the requirements for the Master's Degree in Technology: Chiropractic, Technikon Natal, 2001. / The purpose of this study was to test the Effectiveness of Proprioceptive Neuromuscular Facilitative Stretching combined with administration of Diclofenac compared to Proprioceptive Neuromuscular Facilitative Stretching and placebo medication for the treatment of Cervical Facet Syndrome in a clinical experimental setting. Neck pain is a common disorder, which can often be attributed to mechanical dysfunction of the cervical spine. The patient with facet syndrome may complain of sudden onset of unilateral neck pain, often with referred pain. Muscle spasm is usually present causing restricted movement. Pain increases with movement and is relieved by rest. The pain is aggravated by hyperextension and relieved by flexion and often follows a sclerotomal rather than a dermatomal pattern. Forty subjects with mechanical neck pain were screened for facet syndrome and randomly divided into two groups of twenty. Each patient received Proprioceptive Neuromuscular Facilitative (PNF) stretching of the Posterior Cervical and Trapezius musculature. In conjunction with this, half the patients received Cataflam D while the other half received placebo medication. The patients were treated five times over a period of two weeks. Both groups were evaluated in terms of subjective and objective clinical findings by making use of questionnaires (Numerical Pain Rating Scale 101, Short Form McGill Pain Questionnaire and the CMCC) and algometer and goniometer measurements respectively. The data was collected at the initial, middle and final treatments for each patient. / M